Platensimycin-berberine chloride co-amorphous drug system: Sustained release and prolonged half-life

• DOI: 10.1016/j.ejpb.2022.09.002
• Publication Date: 2022-09-07T16:16:55Z
• Authors: Zhe Wang; Xin Chen; Duanxiu Li; Enhe Bai; Hailu Zhang; Yanwen Duan; Yong Huang
• Keywords: Methicillin-Resistant Staphylococcus aureus; 0303 health sciences; Berberine; Calorimetry, Differential Scanning; Adamantane; Anti-Bacterial Agents; Rats; 3. Good health; 03 medical and health sciences; Chlorides; Drug Stability; Solubility; X-Ray Diffraction; Delayed-Action Preparations; Spectroscopy, Fourier Transform Infrared; Animals; Aminobenzoates; Anilides; Fatty Acid Synthases; Powders; Half-Life

Co-amorphous technology is an emerging approach for pharmaceutical engineering of drugs and drug leads with improved physicochemical properties and bioavailability. Platensimycin (PTM) is a promising natural antibiotic lead that acts on bacterial fatty acid synthase and exhibits excellent antibacterial activity. Despite great strides to improve its poor pharmacokinetics by medicinal chemistry and nanotechnology, there are no convenient oral delivery systems developed. Here, a co-amorphous system of PTM and berberine chloride (BCL) was developed for oral delivery of PTM. Co-amorphous PTM-BCL was prepared by rotary vacuum evaporation method, and systematically characterized by powder X-ray diffraction, temperature modulated differential scanning calorimetry, Fourier transform infrared spectroscopy (FTIR), and X-ray photoelectron spectroscopy (XPS). Compared with PTM or BCL alone, the equilibrium solubility and dissolution rate of both of them in the co-amorphous systems decreased significantly, showing the characteristics of sustained release. The molecular interactions between PTM and BCL were mediated by strong charged-mediated hydrogen bonds, based on FTIR, XPS, and NMR-based techniques. The co-amorphous PTM-BCL system showed excellent physiochemical stability at room and elevated (40 °C) temperature under dry conditions. The combination of PTM and BCL showed increased killing of a clinical isolated methicillin-resistant Staphylococcus aureus strain in killing checkerboard assays. Finally, co-amorphous PTM-BCL exhibited 2- or 3-fold longer half-life in rats than that of crystalline and amorphous PTM upon oral administration, respectively. Our study suggests a rational approach to realize the full potential of potent antibiotic PTM, which may be conveniently adapted for engineering of other important pharmaceutics.